Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IDXX
stocks logo

IDXX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.07B
+12.37%
2.929
+11.78%
1.10B
+10.47%
3.413
+15.32%
1.19B
+7.57%
3.898
+7.39%
Estimates Revision
The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 1.09% over the past three months. During the same period, the stock price has changed by 11.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.71%
In Past 3 Month
Stock Price
Go Up
up Image
+11.58%
In Past 3 Month
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 785.63 USD with a low forecast of 750.00 USD and a high forecast of 830.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 785.63 USD with a low forecast of 750.00 USD and a high forecast of 830.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 717.470
sliders
Low
750.00
Averages
785.63
High
830.00
Current: 717.470
sliders
Low
750.00
Averages
785.63
High
830.00
Piper Sandler
Neutral
maintain
$700 -> $775
2025-11-10
Reason
Piper Sandler
Price Target
$700 -> $775
2025-11-10
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Idexx Laboratories to $775 from $700 following quarterly results. The firm keeps a Neutral rating on the shares.
BTIG
Buy
maintain
$785 -> $830
2025-11-04
Reason
BTIG
Price Target
$785 -> $830
2025-11-04
maintain
Buy
Reason
BTIG raised the firm's price target on Idexx Laboratories to $830 from $785 and keeps a Buy rating on the shares after its "strong" Q3 earnings beat. The growth was broad based and the quality of the beat was high, the analyst tells investors in a research note.
UBS
Neutral
maintain
$710 -> $750
2025-11-04
Reason
UBS
Price Target
$710 -> $750
2025-11-04
maintain
Neutral
Reason
UBS raised the firm's price target on Idexx Laboratories to $750 from $710 and keeps a Neutral rating on the shares. The macro is showing signs of life, the analyst tells investors in a research note.
Morgan Stanley
Overweight
maintain
$765 -> $805
2025-11-04
Reason
Morgan Stanley
Price Target
$765 -> $805
2025-11-04
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Idexx Laboratories to $805 from $765 and keeps an Overweight rating on the shares. Following a "strong" Q3 report and lifted 2025 guidance, the firm came away " incrementally constructive," the analyst tells investors. Following the report, the firm has "greater conviction in its growth prospects with one of the most compelling innovation pipelines in the company's history," the analyst added.
Stifel
Jonathan Block
Buy
upgrade
$700 -> $775
2025-11-03
Reason
Stifel
Jonathan Block
Price Target
$700 -> $775
2025-11-03
upgrade
Buy
Reason
Stifel analyst Jonathan Block raised the firm's price target on Idexx Laboratories to $775 from $700 and keeps a Buy rating on the shares. The firm says that its upgrade thesis from last week was that visits get modestly better, a soft landing occurs with price, and the "IDEXX premium" continues to strengthen. This should allow CAG Dx recurring revenue growth to accelerate in 2026/2027, which Stifel believes will support the stock's multiple at current levels. These variables all played out in the quarter as visits and the "premium" improved, and price has proved somewhat durable, the firm argues.
Leerink
Outperform
maintain
$745 -> $785
2025-11-03
Reason
Leerink
Price Target
$745 -> $785
2025-11-03
maintain
Outperform
Reason
Leerink raised the firm's price target on Idexx Laboratories to $785 from $745 and keeps an Outperform rating on the shares. The firm notes the company's Q3 print and guide increase were impressive, serving as another reminder of its best-in-class competitive positioning and amenable end markets. Idexx posted strong organic growth in the U.S. and International CAG recurring Dx businesses, underscoring the size of the current diagnostic market opportunity and the company's ability to execute against it. Idexx clearly continues to execute well, using the growth levers that it has at its disposal to drive results, says Leerink.
See All Ratings

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 52.01, compared to its 5-year average forward P/E of 50.68. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
50.68
Current PE
52.01
Overvalued PE
62.91
Undervalued PE
38.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
35.43
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
43.84
Undervalued EV/EBITDA
27.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.31
Current PS
0.00
Overvalued PS
13.79
Undervalued PS
8.83
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 764.05% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IDXX News & Events

Events Timeline

(ET)
2025-11-03
09:55:01
Significant Early Gainers in Liquid Options on November 3rd
select
2025-11-03
06:34:32
Idexx Laboratories increases FY25 EPS forecast to $12.81-$13.01, up from $12.40-$12.76
select
2025-11-03
06:31:29
Idexx Laboratories Announces Q3 Earnings Per Share of $3.40, Exceeding Consensus Estimate of $3.14
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
02:39 AMCNBC
A lesser-known medical device stock shows potential for a 20% increase, based on chart analysis.

  • Sector Performance: The health care sector, particularly medical devices, is showing signs of recovery, with the SPDR Health Care Select Sector ETF (XLV) and biotech stocks performing well, while Idexx Labs (IDXX) has reached all-time highs.

  • Stock Analysis: Steris (STE), a leader in sterilization and infection prevention, is highlighted as a strong investment opportunity, showing a favorable risk/reward setup with potential gains of 20%-25% as it breaks above key resistance levels.

  • Market Trends: The medical device sector is gaining traction, with Steris outperforming the sector average, indicating a rotation of investor interest towards this area.

  • Investment Advice: The content emphasizes the importance of setting risk parameters and suggests consulting a financial advisor before making investment decisions, as the information provided is general and not tailored to individual circumstances.

[object Object]
Preview
6.5
12-04NASDAQ.COM
Reasons to Consider Adding CONMED Stock to Your Portfolio Today

  • Growth Potential: CONMED Corporation is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs).

  • Challenges and Delays: The company faces tariff-related gross margin pressures and delays in AirSeal adoption due to the integration of Intuitive Surgical’s dV5 system, which includes its own insufflation system, impacting immediate sales opportunities.

  • Supply Chain Improvements: Progress in supply chain recovery is expected to enhance product availability and support growth in the orthopedics business, although the full recovery may take several quarters.

  • Strategic Focus: A portfolio review is guiding CONMED to concentrate on high-return segments such as minimally invasive surgery and orthopedic soft-tissue repair, aiming to improve margins and long-term competitiveness.

[object Object]
Preview
9.0
12-02NASDAQ.COM
Baxter Announces Recall for Permanent Withdrawal of Life2000 Ventilator

  • Recall of Life2000 Ventilation System: Baxter has recalled its Life2000 Ventilation System due to a serious cybersecurity issue that could lead to unauthorized access and potential failure of life-support functions, with the FDA categorizing this recall as the most serious type.

  • Market Impact and Stock Performance: Despite the recall, Baxter's stock price has increased by 0.9% since the FDA notice, although the company's stock has declined 34.6% this year compared to the industry’s 4.9% gain.

  • Previous Recalls and Safety Concerns: This recall follows two earlier recalls in 2023 and 2024 related to battery-charging issues and oxygen-desaturation risks, with no reported serious injuries or deaths linked to the current cybersecurity issue as of April 2025.

  • Recommendations for Users: Baxter has advised users to stop using the Life2000 ventilators and consult healthcare providers for alternative medical equipment, while healthcare facilities are instructed to discontinue the use of all Life2000 devices.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IDEXX Laboratories Inc (IDXX) stock price today?

The current price of IDXX is 717.47 USD — it has decreased -1.17 % in the last trading day.

arrow icon

What is IDEXX Laboratories Inc (IDXX)'s business?

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

arrow icon

What is the price predicton of IDXX Stock?

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 785.63 USD with a low forecast of 750.00 USD and a high forecast of 830.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?

IDEXX Laboratories Inc revenue for the last quarter amounts to 1.11B USD, increased 13.29 % YoY.

arrow icon

What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?

IDEXX Laboratories Inc. EPS for the last quarter amounts to 3.40 USD, increased 21.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for IDEXX Laboratories Inc (IDXX)'s fundamentals?

The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 1.09% over the past three months. During the same period, the stock price has changed by 11.58%.
arrow icon

How many employees does IDEXX Laboratories Inc (IDXX). have?

IDEXX Laboratories Inc (IDXX) has 11000 emplpoyees as of December 05 2025.

arrow icon

What is IDEXX Laboratories Inc (IDXX) market cap?

Today IDXX has the market capitalization of 57.29B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free